Positive PEACHTREE Data to be Highlighted at Euretina 2018

Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming European Society of Retina Specialists (EURETINA) Congress 2018 in Vienna, Austria.

Dr. Neumann’s presentation, titled “Suprachoroidally Injected CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study,” is scheduled for Thursday, September 20 at 12:24 p.m. CEST.

“This, the first presentation of the PEACHTREE data at a scientific meeting outside of the United States, comes at an opportune time as we plan to pursue marketing authorizations for suprachoroidal CLS-TA to treat macular edema associated with non-infectious uveitis in Europe and other jurisdictions,” said Clearside’s Chief Executive Officer and President, Daniel White.